vimarsana.com

Latest Breaking News On - Institutional trading of syros pharmaceuticals - Page 1 : vimarsana.com

Syros Pharmaceuticals (NASDAQ:SYRS) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright restated their buy rating on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) in a report issued on Wednesday, Benzinga reports. The firm currently has a $15.00 price target on the stock. HC Wainwright also issued estimates for Syros Pharmaceuticals’ Q2 2024 earnings at ($0.73) EPS, Q3 2024 earnings at ($0.74) EPS, Q4 […]

Syros Pharmaceuticals (NASDAQ:SYRS) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) in a report published on Wednesday morning, Benzinga reports. HC Wainwright currently has a $15.00 target price on the stock. A number of other research analysts have also recently issued reports on the stock. StockNews.com cut shares of Syros Pharmaceuticals […]

Syros Pharmaceuticals (NASDAQ:SYRS) Stock Price Passes Below 50 Day Moving Average of $5 94

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Free Report)’s stock price passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $5.94 and traded as low as $5.28. Syros Pharmaceuticals shares last traded at $5.44, with a volume of 199,560 shares traded. Wall Street Analysts […]

Syros Pharmaceuticals (NASDAQ:SYRS) Rating Lowered to Sell at StockNews com

Syros Pharmaceuticals (NASDAQ:SYRS – Get Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday. Syros Pharmaceuticals Price Performance Shares of NASDAQ SYRS traded down $0.10 during mid-day trading on Tuesday, reaching $6.46. The company had a […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.